DNA
Price
$11.33
Change
+$0.31 (+2.81%)
Updated
Sep 3 closing price
Capitalization
670.73M
RXRX
Price
$4.63
Change
-$0.03 (-0.64%)
Updated
Sep 3 closing price
Capitalization
2.02B
62 days until earnings call
Interact to see
Advertisement

DNA vs RXRX

Header iconDNA vs RXRX Comparison
Open Charts DNA vs RXRXBanner chart's image
Ginkgo Bioworks Holdings
Price$11.33
Change+$0.31 (+2.81%)
Volume$1.49M
Capitalization670.73M
Recursion Pharmaceuticals
Price$4.63
Change-$0.03 (-0.64%)
Volume$12.65M
Capitalization2.02B
DNA vs RXRX Comparison Chart in %
Loading...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNA vs. RXRX commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNA is a Buy and RXRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (DNA: $11.02 vs. RXRX: $4.66)
Brand notoriety: DNA and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNA: 164% vs. RXRX: 53%
Market capitalization -- DNA: $670.73M vs. RXRX: $2.02B
DNA [@Biotechnology] is valued at $670.73M. RXRX’s [@Biotechnology] market capitalization is $2.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNA’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • DNA’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, DNA is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNA’s TA Score shows that 2 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • DNA’s TA Score: 2 bullish, 5 bearish.
  • RXRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than DNA.

Price Growth

DNA (@Biotechnology) experienced а -13.77% price change this week, while RXRX (@Biotechnology) price change was -3.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

RXRX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.02B) has a higher market cap than DNA($671M). DNA YTD gains are higher at: 12.220 vs. RXRX (-31.065). DNA has higher annual earnings (EBITDA): -292.97M vs. RXRX (-583.64M). RXRX has more cash in the bank: 525M vs. DNA (474M). RXRX has less debt than DNA: RXRX (88.1M) vs DNA (429M). DNA has higher revenues than RXRX: DNA (231M) vs RXRX (64.5M).
DNARXRXDNA / RXRX
Capitalization671M2.02B33%
EBITDA-292.97M-583.64M50%
Gain YTD12.220-31.065-39%
P/E RatioN/AN/A-
Revenue231M64.5M358%
Total Cash474M525M90%
Total Debt429M88.1M487%
TECHNICAL ANALYSIS
Technical Analysis
DNARXRX
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 13 days ago
82%
Bullish Trend 13 days ago
85%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PLBBX39.72N/A
N/A
Plumb Balanced Investor
UIISX18.93-0.05
-0.26%
Victory Income Stock Institutional
EVTMX16.95-0.09
-0.53%
Eaton Vance Dividend Builder A
TIBOX31.20-0.22
-0.70%
Thornburg Investment Income Builder R6
LGFEX21.12-0.21
-0.98%
Franklin International Equity FI

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with RXRX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
-13.02%
RXRX - DNA
53%
Loosely correlated
-0.85%
ABCL - DNA
49%
Loosely correlated
-3.11%
CRSP - DNA
49%
Loosely correlated
+1.60%
ABSI - DNA
48%
Loosely correlated
-2.09%
NTLA - DNA
48%
Loosely correlated
+0.40%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-0.85%
CRSP - RXRX
68%
Closely correlated
+1.60%
BEAM - RXRX
63%
Loosely correlated
-0.31%
ABSI - RXRX
62%
Loosely correlated
-2.09%
ABCL - RXRX
58%
Loosely correlated
-3.11%
NTLA - RXRX
55%
Loosely correlated
+0.40%
More